Drug intelligence / Profile preview

Lupeol

Development stage
Preclinical
Modality
Classical Binding Small Molecules → Small Molecules
Administration
Oral, Topical
01

Overview

Lupeol is a naturally occurring pentacyclic triterpenoid found in many fruits and vegetables, including white cabbage, green pepper, strawberry, olive, mangoes, and grapes[3][5][6]. It has been investigated primarily as an anti-inflammatory agent and for the treatment of acne[1][2]. Lupeol exhibits a broad range of pharmacological activities such as anti-inflammatory, antioxidant, antitumor/anticancer (including chemopreventive), antimicrobial, antiprotozoal, immunomodulatory, anti-angiogenic effects and cholesterol-lowering properties[3][4][5][6]. Mechanistically, lupeol acts as a multi-target agent. Its anti-inflammatory effects are mediated by modulation of key molecular pathways including nuclear factor kappa B (NFκB), cFLIP, Fas receptor signaling pathway (apoptosis), phosphatidylinositol-3-kinase/Akt pathway (PI3K/Akt), Wnt/β-catenin signaling pathway; it also reduces pro-inflammatory cytokines such as IL-4 from T-helper type 2 cells and inhibits production of prostaglandin E2 (PGE2) in macrophages[3][5][7][8]. In cancer models it induces apoptosis via mitochondrial-mediated pathways involving increased reactive oxygen species (ROS) levels and altered Bax/Bcl-2 ratio leading to caspase activation[4]. Lupeol has also shown activity against dipeptidyl peptidase-4 at high concentrations. Additional reported actions include inhibition of cell migration/invasion through suppression of RhoA–ROCK1 signaling in colorectal cancer cells[6], neuroprotection via p38 MAPK modulation[7], wound healing enhancement by docking with GSK3β protein[3], contraceptive effect through inhibition of sperm calcium channel CatSper[5], downregulation of TNF-alpha and VEGFR-2 for its anti-cancer/antiangiogenic effects [5], cytoprotective action against free-radical-induced damage [6] and reduction in hypercholesterolemia [4]. Lupeol is considered investigational; it is not approved for any indication but continues to be studied preclinically for inflammation-related disorders and various cancers.

Other names
lupeol
02

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)VEGFR2 (Vascular endothelial growth factor receptor 2)IL-4 (Interleukin 4)NF-κBTNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Lupeol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lupeol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call